Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek ...

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 13,196 call options on the stock. This represents an increase of ...

H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...

Investors with a lot of money to spend have taken a bearish stance on Reviva Pharmaceuticals (NASDAQ:RVPH). And retail traders should know. We noticed this today when the trades showed up on ...

Reviva Pharmaceuticals Holdings Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 90.48%. The profit margin, also known as the revenue ratio or gross ...

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage ...

Stock Trading Recap. On Friday, Reviva Pharmaceuticals Holdings Inc (RVPH) stock saw a decline, ending the day at $1.77 which represents ...

Fintel reports that on January 10, 2025, Maxim Group upgraded their outlook for Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) from Hold to Buy. Analyst Price Forecast Suggests 724.68% Upside As ...